Network News
How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these […]
read more
Partnership Between Heidelberg and Harvard: Implementation of Initial Projects Begins
23 joint initiatives selected for funding – focus on long-term cooperation The strategic partnership between Heidelberg University and Harvard University is now seeing the launch of the first joint projects by researchers from the two institutions. In August 2025, their respective leading representatives had signed a Memorandum of Understanding in order to broaden the existing […]
read more
Award for Heidelberg Evolutionary Geneticist
Henrik Kaessmann receives Ernst Schering Prize for fundamental contributions to understanding mammalian evolution Prof. Dr Henrik Kaessmann has been selected to receive the 2026 Ernst Schering Prize for his pioneering research into the evolutionary origins and genetic regulation of organ development and organ function. The award, which comes with 50,000 euros in prize money, is […]
read more
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech has strengthened its financial position to support the closing of its business combination with Voyager Acquisition Corp. and support advancement of its pipeline of BiTAC-TCE and BiTAC-ADC programs toward clinical development and through initial value inflection points. ZURICH, SWITZERLAND – May 28, 2026 – VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel […]
read more
Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network
Effective June 1, 2026, the Supervisory Board has appointed Hanns-Peter Knaebel, Chairman of the Executive Board, to serve as Chief Medical Officer. This move will ensure that the dynamic phase of medical strategy development and transformation within the group is overseen and managed centrally by the full Executive Board. Full Text in German below. Professor […]
read more
ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions
HEILBRONN, Germany, May 14, 2026 – ProtaGene today announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end testing solution across the entire biopharmaceutical product lifecycle, from early-stage development through GMP release testing. ProtaGene’s expertise in advanced protein […]
read more
Universität Heidelberg Successful with Application for Collaborative Research Centre
DFG funds extended CRC with approximately 17.4 million euros Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG) with a grant application for a major research consortium: The Collaborative Research Centre “Molecular Circuits of Heart Disease” (CRC 1550), based at the Medical Faculty Heidelberg, is entering a second […]
read more
HI-TAC: Karina Yaniv Appointed as New Scientific Director
Helmholtz Institute for Translational AngioCardioScience brings together expertise in cardiac, vascular and systems biology Prof. Dr Karina Yaniv of the Weizmann Institute of Science has been appointed as new Scientific Director of the Helmholtz Institute for Translational AngioCardioScience in Mannheim/Heidelberg (HI-TAC), the Max Delbrück Center in Berlin and Heidelberg University announced in cooperation with the […]
read more
Unlocking the Lung’s Ability to Heal
NK Cell Immunotherapy offers New Hope for Fibrosis Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse […]
read more
